ETNB - 89bio GAAP EPS of -$0.45 beats by $0.08
2023-11-08 17:15:44 ET
More on 89bio
- 89bio's Low Price Presents An Opportunity
- 89bio: Risk And Reward Balance In NASH Therapeutics
- 89bio gains FDA breakthrough status for NASH candidate
- 89bio gains as UBS starts at Buy; cites upcoming data from Akero
- Seeking Alpha’s Quant Rating on 89bio
For further details see:
89bio GAAP EPS of -$0.45 beats by $0.08